An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa

Trial Profile

An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs HP 802247 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors Smith & Nephew Biotherapeutics
  • Most Recent Events

    • 30 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top